Clinical Trials Browser

Melanoma, Skin Neoplasms

Melanoma, Meningeal Neoplasms

Melanoma, Neoplasm Metastasis

Skin Neoplasms, Carcinoma, Merkel Cell

Melanoma, Skin Neoplasms

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma

Melanoma, Neoplasms, Skin Neoplasms

Uveal Melanoma, Eye Neoplasms, Neoplasms

Kidney Neoplasms, Melanoma

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Uveal Melanoma, Neoplasm Metastasis

Melanoma, Neoplasms, Skin Neoplasms

Melanoma, Neoplasm Metastasis

Melanoma, Skin Neoplasms

Melanoma, Skin Neoplasms

Kidney Neoplasms, Melanoma

Melanoma, Melanoma, Experimental, Neoplasms, Skin Neoplasms

Melanoma, Skin Neoplasms

Melanoma, Skin Neoplasms

Breast Neoplasms, Melanoma, Neoplasm Metastasis

Kidney Neoplasms, Melanoma

Melanoma, Neoplasm Metastasis, Neoplasms

Clinical Trials

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

SBRT/IL-2

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

TIL Therapy in cSCC and MCC

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

PragmaTIL

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Radiation and Combination Immunotherapy for Melanoma

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

METILDA

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Biochemotherapy With Temozolomide for Metastatic Melanoma

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Interleukin-2 in Metastatic Melanoma

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma

Drosophila-generated CTL

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases

MEL36

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence